Thomas Barton

Director at Myrtelle.

New York, NY
Myrtelle

Raised on Myrtelle filings

$24.2M

of $45M offered across 2 Form D filings

Form D filings: 2
Teammates: 3
Last filing: Jul 2, 2026

Company

Biotech · New York, NY

Gene therapy for Canavan disease

Gene therapy for Canavan disease

Investors: 1
Founded: 2021
Still open: $20.8M

Investors: 1
Sector: Biotech
Founded: 2021
HQ: New York, NY

Myrtelle filings

Myrtelle Form D filings
Filed	Security	Sold of offered	Filing
Jul 2, 2026	Security to be acquired	$16.7M/ $30M	Form D
Mar 21, 2025	Debt	$7.5M/ $15M	Form D

Security to be acquiredFiled Jul 2, 2026Form D
$16.7M/ $30M
DebtFiled Mar 21, 2025Form D
$7.5M/ $15M

Works with

Also named on Myrtelle filings

Adiran StecykChief Executive Officer and Director, Form D signerForm D signer Adrian StecykChief Executive Officer and Director, Form D signerForm D signer Michael MuhonenDirector